Cilostazol indications and usage: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 10: Line 10:
{{Reflist}}
{{Reflist}}


{{FDA}}
[[Category:Cardiovascular Drugs]]
 
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 22:48, 28 February 2014

Cilostazol
PLETAL® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Studies
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Indications and Usage

PLETAL is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.[1]

References

  1. "PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.]".